Stanford inventors in the lab of Dr. Katrin Svensson have discovered an endogenous peptide hormone that shows promise in treating obesity and diabetes.
SparseGMM, is a new algorithm which is a novel statistical approach for identifying drug targets in cancer patients and other diseases by more accurately modeling biological pathways.
Stanford inventors have developed a single cell screening platform that can be used to predict the therapeutic effects of osteoarthritis (OA) drugs on individual patients by defining consequent changes in the cellular landscape.
Vibrational spectroscopy, including infrared and Raman optical spectroscopy, is an instrumental technique for fingerprinting molecular structures and the chemical compositions of different materials.
Stanford researchers have designed a new 3-dimensional (3D) hydrogel cell culture system that models native tissue environment with precise control over gelation and degradation properties.
Stanford scientists in Dr. Paul Wender's lab have developed a novel method to synthesize tigilanol tiglate (EBC-46) and related compounds from readily available starting materials.
Researchers at Stanford have developed synthetic transcription elongation factors (Syn-TEFs) to treat proliferative diseases, including repeat expansion mutations in cancer.
Stanford researchers have engineered yeast strains for de novo biosynthesis of tetrahydropapaverine (THP) and a semi-synthetic production of papaverine with high efficiency.
Stanford researchers at the Snyder Lab have developed a method for simultaneously measuring thousands of proteins, lipids, and metabolites from home-collected 10 ?L blood samples in conjunction with wearable sensors.
Fast, accurate and cheap synthesis of ultralong strands of DNA is an essential foundation for synthetic DNA technologies such as cellular programming and engineering.
A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.